Beamion LUNG-1

Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy

Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...

By cGxPwire Editor
May 23, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Beamion LUNG-1

Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy